- Home
- FLGC vs MBRX Comparison
FLGC vs MBRX Comparison
Compare FLGC & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLGC
- MBRX
- Stock Information
- Founded
- FLGC 2019
- MBRX 2015
- Country
- FLGC United States
- MBRX United States
- Employees
- FLGC N/A
- MBRX N/A
- Industry
- FLGC Biotechnology: Pharmaceutical Preparations
- MBRX Biotechnology: Pharmaceutical Preparations
- Sector
- FLGC Health Care
- MBRX Health Care
- Exchange
- FLGC Nasdaq
- MBRX Nasdaq
- Market Cap
- FLGC 15.9M
- MBRX 12.9M
- IPO Year
- FLGC 2021
- MBRX 2016
- Fundamental
- Price
- FLGC $0.61
- MBRX $0.31
- Analyst Decision
- FLGC Buy
- MBRX Strong Buy
- Analyst Count
- FLGC 2
- MBRX 3
- Target Price
- FLGC $4.00
- MBRX $5.33
- AVG Volume (30 Days)
- FLGC 106.1K
- MBRX 5.2M
- Earning Date
- FLGC 08-11-2025
- MBRX 08-13-2025
- Dividend Yield
- FLGC N/A
- MBRX N/A
- EPS Growth
- FLGC N/A
- MBRX N/A
- EPS
- FLGC N/A
- MBRX N/A
- Revenue
- FLGC $53,260,000.00
- MBRX N/A
- Revenue This Year
- FLGC N/A
- MBRX N/A
- Revenue Next Year
- FLGC N/A
- MBRX N/A
- P/E Ratio
- FLGC N/A
- MBRX N/A
- Revenue Growth
- FLGC N/A
- MBRX N/A
- 52 Week Low
- FLGC $0.42
- MBRX $0.25
- 52 Week High
- FLGC $2.11
- MBRX $4.71
- Technical
- Relative Strength Index (RSI)
- FLGC 42.89
- MBRX 24.39
- Support Level
- FLGC $0.62
- MBRX $0.25
- Resistance Level
- FLGC $0.72
- MBRX $0.42
- Average True Range (ATR)
- FLGC 0.06
- MBRX 0.06
- MACD
- FLGC -0.01
- MBRX -0.03
- Stochastic Oscillator
- FLGC 14.79
- MBRX 13.07
About FLGC Flora Growth Corp.
Flora Growth Corp is a multi-national cannabis company that manufactures and distributes consumer packaged goods, cultivates and distributes medicinal cannabis, and distributes pharmaceutical products. Its reportable segments are: the commercial and wholesale segment (FGH and Cosechemos subsidiaries) and the house of brands segment (JustCBD, Vessel, and Kasa Wholefoods Company subsidiaries). Geographically, the company generates revenue from the United States, Germany, Australia, and the United Kingdom. It generates revenue as a distributor of pharmaceutical goods, and a manufacturer and reseller of a range of cannabis-based and complementary products.
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.